What are the responsibilities and job description for the Associate Scientist I/II: Biomolecular Interaction Characterization position at Dragonfly Therapeutics?
Associate Scientist I / II : Biomolecular Interaction Characterization
Dragonfly Therapeutics is seeking a highly motivated and talented Associate Scientist I / II to be a valuable member of the Protein Analytics group, title commensurate with experience. In this role you, will contribute to the development of next-generation biologics including multispecific antibodies, cytokine-fusions, and novel agents for the treatment of cancer, autoimmune disease, neuro-inflammation, and beyond. The successful candidate will perform detailed biomolecular interaction analyses to determine kinetic rates, affinities, epitope bins, and other critical binding properties using state of the art biosensing technologies.
Responsibilities (including but not limited to) :
- Design and execute biomolecular interaction experiments with recombinant, membrane-stabilized, and cell expressed proteins using Surface Plasmon Resonance (SPR) and Kinetic Exclusion Assay (KinExA) platforms
- Characterize recombinant proteins by SEC-MALS, SDS-PAGE, and intact mass analysis
- Purify recombinant proteins on an KTA Pure FPLC using affinity, ion exchange, and size exclusion chromatography
- Perform cell culture on mammalian cells expressing desired protein targets
- Document observations and data in detailed electronic lab notebooks
- Analyze and present data at group meetings
Qualifications :
About Dragonfly
Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel multispecific antibody technology to harness the body's immune system to bring breakthrough treatments to patients. In addition to its wholly owned clinical assets, Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platform, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas.
Our mission is to revolutionize disease treatment by inventing natural killer cell-based therapies for vastly improved patient outcomes. We believe in a small team with a big impact.
